Prognostic factors for survival from relapse
| . | No. deaths . | No. patients . | O/E ratio . | 5-y OS, % . | CI . | Log-rank P . |
|---|---|---|---|---|---|---|
| Ph status | >.999 | |||||
| Positive | 397 | 433 | 1.0 | 6 | 4-9 | |
| Negative | 109 | 120 | 1.0 | 9 | 3-14 | |
| Sex | .006 | |||||
| Male | 348 | 382 | .09 | 8 | 5-11 | |
| Female | 211 | 227 | 1.2 | 3 | 0-6 | |
| Age at diagnosis | <.001 (trend) | |||||
| Younger than 20 y | 101 | 117 | 0.7 | 12 | 6-18 | |
| 20-34 y | 212 | 236 | 0.9 | 7 | 4-11 | |
| 35-49 y | 174 | 182 | 1.2 | 4 | 1-7 | |
| 50 y or older | 72 | 74 | 1.5 | 3 | 0-6 | |
| WBC count at diagnosis | .05 (trend) | |||||
| Less than 10 × 109/L | 227 | 248 | 0.9 | 5 | 2-8 | |
| 10-49 × 109/L | 161 | 178 | 1.0 | 9 | 4-13 | |
| More than 50 × 109/L | 169 | 181 | 1.1 | 6 | 3-10 | |
| Immunophenotype | .06 (heterogeneity) | |||||
| Pre-B | 368 | 409 | 0.9 | 8 | 5-10 | |
| T | 87 | 92 | 1.1 | 5 | 0-10 | |
| Mature B | 12 | 12 | 1.2 | 0 | — | |
| Null | 30 | 30 | 1.3 | 0 | — | |
| Mix | 21 | 22 | 1.5 | 5 | 0-13 | |
| Therapy in CR1* | >.999 (heterogeneity) | |||||
| Chemotherapy | 390 | 429 | 1.0 | 7 | 5-10 | |
| Autologous HSCT | 76 | 80 | 1.05 | 3 | 0-8 | |
| Allo-HSCT | 70 | 77 | 1.0 | 9 | 2-16 | |
| Time from diagnosis to relapse | <.001 | |||||
| Less than 2 y | 463 | 493 | 1.0 | 5 | 3-8 | |
| 2 y or longer | 96 | 116 | 0.7 | 11 | 4-17 | |
| Site of relapse | .004 (heterogeneity) | |||||
| BM | 482 | 523 | 1.0 | 6 | 4-8 | |
| BM + CNS | 33 | 33 | 1.7 | 0 | — | |
| CNS | 19 | 22 | 0.9 | 0 | — | |
| Extramedullary | 20 | 23 | 0.7 | 14 | 0-28 |
| . | No. deaths . | No. patients . | O/E ratio . | 5-y OS, % . | CI . | Log-rank P . |
|---|---|---|---|---|---|---|
| Ph status | >.999 | |||||
| Positive | 397 | 433 | 1.0 | 6 | 4-9 | |
| Negative | 109 | 120 | 1.0 | 9 | 3-14 | |
| Sex | .006 | |||||
| Male | 348 | 382 | .09 | 8 | 5-11 | |
| Female | 211 | 227 | 1.2 | 3 | 0-6 | |
| Age at diagnosis | <.001 (trend) | |||||
| Younger than 20 y | 101 | 117 | 0.7 | 12 | 6-18 | |
| 20-34 y | 212 | 236 | 0.9 | 7 | 4-11 | |
| 35-49 y | 174 | 182 | 1.2 | 4 | 1-7 | |
| 50 y or older | 72 | 74 | 1.5 | 3 | 0-6 | |
| WBC count at diagnosis | .05 (trend) | |||||
| Less than 10 × 109/L | 227 | 248 | 0.9 | 5 | 2-8 | |
| 10-49 × 109/L | 161 | 178 | 1.0 | 9 | 4-13 | |
| More than 50 × 109/L | 169 | 181 | 1.1 | 6 | 3-10 | |
| Immunophenotype | .06 (heterogeneity) | |||||
| Pre-B | 368 | 409 | 0.9 | 8 | 5-10 | |
| T | 87 | 92 | 1.1 | 5 | 0-10 | |
| Mature B | 12 | 12 | 1.2 | 0 | — | |
| Null | 30 | 30 | 1.3 | 0 | — | |
| Mix | 21 | 22 | 1.5 | 5 | 0-13 | |
| Therapy in CR1* | >.999 (heterogeneity) | |||||
| Chemotherapy | 390 | 429 | 1.0 | 7 | 5-10 | |
| Autologous HSCT | 76 | 80 | 1.05 | 3 | 0-8 | |
| Allo-HSCT | 70 | 77 | 1.0 | 9 | 2-16 | |
| Time from diagnosis to relapse | <.001 | |||||
| Less than 2 y | 463 | 493 | 1.0 | 5 | 3-8 | |
| 2 y or longer | 96 | 116 | 0.7 | 11 | 4-17 | |
| Site of relapse | .004 (heterogeneity) | |||||
| BM | 482 | 523 | 1.0 | 6 | 4-8 | |
| BM + CNS | 33 | 33 | 1.7 | 0 | — | |
| CNS | 19 | 22 | 0.9 | 0 | — | |
| Extramedullary | 20 | 23 | 0.7 | 14 | 0-28 |
Ph indicates Philadelphia chromosome; pre-B, precursor B; mix, mixed lineage; allo-HSCT, matched or unrelated donor HSCT; and —, not applicable.
Twenty-four patients were excluded: 7 underwent transplantation before remission, 3 with reduced-intensity conditioning regimens, 1 mismatched-related, 1 with unknown-type SCT, 1 with SCT on an unknown date, and 11 who died before 12 weeks and hence could not possibly have reached transplantation.